STOCK TITAN

Boston Scientific sets 2027 bonus cap at 225% of target

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

On November 17, 2026, Boston Scientific Corporation (BSX) approved its 2027 annual cash bonus plan and two executive performance-share programs. The bonus plan covers the January 1, 2027–December 31, 2027 performance year; companywide goals include global sales and adjusted earnings per share, and an individual payout can reach 225% of target.

The performance-share programs measure relative total shareholder return against companies in the S&P 500 Healthcare Index and organic net sales growth against the company’s financial plan over January 1, 2027–December 31, 2029; awards range from 0% to 200% of target. Effective January 1, 2027, independent director David S. Wichmann will become Lead Independent Director, succeeding Edward J. Ludwig, who will remain on the Board.

Filing Explained

The filing sets future incentive terms: cash payouts remain quality-adjustable, while share awards require performance and payment eligibility.

Form 8-K reports specified material events; here, the Boston Scientific Board approved a 2027 cash bonus plan and two performance-share programs for 2027–2029. The equity programs provide for restricted-stock-unit awards only if relevant program criteria are met.

For the cash plan, the company-wide distribution percentage ranges from 0% to 150% based on global sales and adjusted earnings per share, after which managers apply an individual modifier of 0% to 150%; the Board may reduce the distribution percentage based on quality performance.

Both equity programs make vesting subject to performance and payment-eligibility criteria, with stated exceptions for change of control or termination due to retirement, death or disability; under each program, a participant who retires before January 1, 2028 forfeits the awards in their entirety.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Dynamic bonus pool 10% or less of total target annual bonuses 2027 Annual Bonus Plan
Applicable distribution percentage 0%–150% Based on company performance against company-wide goals
Individual performance modifier 0%–150% Assigned by managers under the 2027 Annual Bonus Plan
Maximum individual bonus payout 225% of target bonus 2027 Annual Bonus Plan
rTSR performance-share awards 0%–200% of target awards Based on the company’s TSR rank
Organic net sales performance-share awards 0%–200% of target awards Based on organic net sales growth performance
Performance period January 1, 2027–December 31, 2029 Three-year period for both performance-share programs
dynamic bonus pool financial
"a dynamic bonus pool, which shall be equal to 10% or less"
applicable distribution percentage financial
"determine the applicable distribution percentage (between 0% - 150%)"
Total Shareholder Return financial
"comparing the Total Shareholder Return ("TSR") of the Company’s common stock"
Total shareholder return is the overall gain an investor gets from owning a stock, combining changes in the share price plus any cash payouts like dividends, and assuming those payouts are reinvested in more shares. Investors use it like a single score that shows the true return on their investment—similar to checking both the growth of a savings account and the interest earned—to compare how well different companies or investments perform over time.
organic net sales growth financial
"comparing the Company’s organic net sales growth"
Organic net sales growth measures how much a company’s core revenue rose from its existing operations, excluding effects from buying or selling businesses and from changes in currency values. Investors use it to see whether customers are actually buying more or paying higher prices — like checking growth from the same orchard year-to-year rather than counting fruit from newly added orchards — which helps assess true demand and underlying business health.
payment eligibility criteria technical
"satisfaction of both the performance criteria and the payment eligibility criteria"
Dodd-Frank Clawback Policy regulatory
"the Company’s Dodd-Frank Clawback Policy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How is the BSX 2027 annual bonus determined?

Boston Scientific’s 2027 plan sets companywide goals for global sales and adjusted earnings per share. After the performance year, the Compensation Committee sets a distribution percentage from 0% to 150%, and managers assign each participant an individual performance modifier from 0% to 150%. An individual payout can reach 225% of target; the dynamic bonus pool is 10% or less of total participant target annual bonuses.

What do the BSX 2027 performance-share programs measure?

The relative total shareholder return program compares Boston Scientific’s return with companies in the S&P 500 Healthcare Index over January 1, 2027–December 31, 2029. The organic net sales program compares growth with the company’s financial plan; its measure excludes foreign currency fluctuations and certain acquisitions and divestitures with less than a full period of comparable net sales. Awards in each program range from 0% to 200% of target and vest only when performance and payment eligibility criteria are met.

Who will be BSX’s Lead Independent Director in 2027?

Independent director David S. Wichmann will become Lead Independent Director effective January 1, 2027, succeeding Edward J. Ludwig, who will continue as a Board member. Wichmann has served as a director since 2021 and is Chair of the Audit Committee and a member of the Risk, Science and Technology Committee.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
0000885725false00008857252026-11-172026-11-170000885725us-gaap:CommonStockMember2026-11-172026-11-170000885725bsx:SeniorNotedue2027Member2026-11-172026-11-17


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________

FORM 8-K
CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
_____________________________________________________________________

Date of Report (Date of earliest event reported): November 17, 2026

BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware1-1108304-2695240
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)

    300 Boston Scientific Way, Marlborough, Massachusetts                 01752-1234
    (Address of principal executive offices)                           (Zip Code)

(508) 683-4000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.01 par value per shareBSXNew York Stock Exchange
0.625% Senior Notes due 2027BSX27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐




Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(i)
2027 Annual Bonus Plan

On November 17, 2026, upon the recommendation of the Executive Compensation and Human Resources Committee (the “Compensation Committee”), the Board of Directors (the “Board”) of Boston Scientific Corporation (the “Company”) approved the Company’s 2027 Annual Bonus Plan effective for the performance year of January 1, 2027 through December 31, 2027 (the “2027 Annual Bonus Plan”).
 
As part of the Company’s overall compensation program, the 2027 Annual Bonus Plan provides an annual cash incentive opportunity for eligible exempt and nonexempt indirect labor or equivalent personnel (including the Company’s named executive officers meeting the eligibility criteria) based on the achievement of certain performance metrics. The 2027 Annual Bonus Plan is substantially similar to the 2026 annual bonus plan and provides:

•for the performance year, an aggregate bonus pool equal to the total target annual bonuses of all plan participants multiplied by the applicable distribution percentage, as well a dynamic bonus pool, which shall be equal to 10% or less of the total target annual bonuses for all plan participants;

•following the end of the performance year, the Compensation Committee shall determine the applicable distribution percentage (between 0% - 150%), based on the Company’s performance measured against Company-wide goals for global sales and adjusted earnings per share; provided the Board maintains its discretion to terminate, suspend or modify the 2027 Annual Bonus Plan and to reduce the applicable distribution percentage based on the Company’s performance relative to its quality objectives and performance of its quality systems; and

•managers will then assign each plan participant under their management an individual performance modifier (between 0% - 150%) based on such participant’s performance, which will be used to determine the participant’s final bonus award, resulting in a maximum payout potential for any individual participant of 0% - 225% of an individual’s target bonus, consistent with prior annual bonus plan years.

Awards to certain executive officers under the 2027 Annual Bonus Plan are subject to (i) the Company’s discretionary recoupment policy, which provides that, to the extent permitted by law, the Company may seek reimbursement of a bonus award in the event of an executive officer’s misconduct or gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company and (ii) the Company’s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board including in response to the requirements of Section 10D of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the final rules of the U.S. Securities and Exchange Commission (the “SEC”) thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing or as otherwise required by law. 
 
This description of the 2027 Annual Bonus Plan does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such plan. A copy of the 2027 Annual Bonus Plan is included in this filing as Exhibit 10.1 and incorporated herein by reference.

(ii)
2027 Performance Share Programs

On November 17, 2026, upon the recommendation of the Compensation Committee, the Board approved the adoption of two performance share programs, the Boston Scientific Corporation 2027 Relative Total Shareholder Return Performance Share Program (the “2027 rTSR PSP”) and the Boston Scientific Corporation 2027 Organic Net Sales Growth Performance Share Program (the “2027 Organic Net Sales PSP”). The 2027 rTSR PSP and the 2027 Organic Net Sales PSP are substantially similar to the 2026 Total Shareholder Return Performance Share Program and the 2026 Organic Net Sales Growth Performance Share Program, respectively. These programs represent an important component of the overall mix of the Company’s long-term incentive program. Under both programs, if the relevant program criteria are met, performance share awards will be granted to the Company’s executive officers in the form of restricted stock units issued under the Company’s Amended and Restated 2011 Long-Term Incentive Plan. Awards to certain executive officers under both programs are subject to (i) the Company’s discretionary recoupment policy, which provides that, to the extent permitted by law, the Company may seek recovery of performance share units in the event of an executive officer’s misconduct or gross dereliction of duty that results in a material violation of Company policy and causes significant harm to the Company, and (ii) the Company’s Dodd-Frank Clawback Policy and any other compensation recovery policy adopted by the Board including in response to the requirements of Section 10D of the Exchange Act, the final rules of the SEC thereunder, and any applicable listing rules or other rules and regulations implementing the foregoing or as otherwise required by law.




(A)
2027 Relative Total Shareholder Return Performance Share Program

The purpose of the 2027 rTSR PSP is to align the Company’s executive compensation program with the interests of stockholders and to reinforce the concept of pay for performance by comparing the Total Shareholder Return (“TSR”) of the Company’s common stock to the TSR of the other companies included in the S&P 500 Healthcare Index over a three-year period beginning on January 1, 2027 and ending on December 31, 2029 (the “Performance Period”). The number of performance shares awarded will be in a range of 0% to 200% of each participant’s target number of awards based on the Company’s TSR rank. Performance share awards will vest only upon satisfaction of both the performance criteria and the payment eligibility criteria set forth in the 2027 rTSR PSP, subject to certain exceptions in the event of a change of control or termination for retirement, death or disability. In the event a participant’s employment with the Company terminates due to retirement, as defined therein, prior to January 1, 2028, the performance share awards will be forfeited in their entirety.

This description of the 2027 rTSR PSP does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such program. A copy of the 2027 rTSR PSP is included in this filing as Exhibit 10.2 and incorporated herein by reference.

     (B)       2027 Organic Net Sales Growth Performance Share Program

The purpose of the 2027 Organic Net Sales PSP is to align the Company’s executive compensation program with the interests of stockholders and to reinforce the concept of pay for performance by providing incentives for the achievement of key business performance objectives critical to the Company’s success. Under the 2027 Organic Net Sales PSP, performance will be measured by comparing the Company’s organic net sales growth, for the three-year period beginning on January 1, 2027 and ending on December 31, 2029 against its financial plan performance for organic net sales, as defined by the 2027 Organic Net Sales PSP. Organic net sales growth, as defined under the 2027 Organic Net Sales PSP, is net sales excluding the impact of foreign currency fluctuation and the impact of certain acquisitions and divestitures for which there are less than a full period of comparable net sales. The number of performance shares awarded will be in a range of 0% to 200% of each participant’s target number of awards, depending on such performance. Performance share awards will only vest upon satisfaction of both the performance criteria and the payment eligibility criteria set forth in the 2027 Organic Net Sales PSP, subject to certain exceptions in the event of a change of control or termination for retirement, death or disability. In the event a participant’s employment with the Company terminates due to retirement, as defined therein, prior to January 1, 2028, the performance share awards will be forfeited in their entirety.

This description of the 2027 Organic Net Sales PSP does not purport to be complete and is subject to and qualified in its entirety by reference to the full text of such program. A copy of the 2027 Organic Net Sales PSP is included in this filing as Exhibit 10.3 and incorporated herein by reference.

Item 8.01     Other Events.

Appointment of New Lead Independent Director

On November 17, 2026, the independent members of the Board appointed David S. Wichmann, an independent director, to serve as Lead Independent Director of the Board, effective January 1, 2027. Mr. Wichmann will succeed Edward J. Ludwig, who has served as Lead Independent Director since 2016 and will continue to serve as a member of the Board. Mr. Wichmann has served as a director of the Company since 2021 and currently serves as Chair of the Audit Committee of the Board and as a member of the Risk, Science and Technology Committee of the Board.

Item 9.01     Financial Statements and Exhibits.

(d)  Exhibits

Exhibit No.          Description

10.1*            Boston Scientific Corporation 2027 Annual Bonus Plan, effective as of January 1, 2027
10.2*            Boston Scientific Corporation 2027 Relative Total Shareholder Return Performance Share Program
10.3*            Boston Scientific Corporation 2027 Organic Net Sales Growth Performance Share Program
104     Cover Page Interactive Data File (embedded within the Inline XBRL document)
* Documents filed or furnished with this report.

    




SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                        
                                
Date:November 17, 2026BOSTON SCIENTIFIC CORPORATION
By:/s/ Susan Thompson
Susan Thompson
Vice President, Chief Corporate Counsel and Assistant Secretary


Filing Exhibits & Attachments

7 documents

Keep reading